The global radiopharmaceutical market is experiencing steady growth, driven by increasing applications in diagnostic imaging and targeted therapy. Radiopharmaceuticals, which are radioactive compounds used in nuclear medicine, are playing a crucial role in the diagnosis and treatment of various medical conditions, including cancer and cardiovascular diseases. The market is witnessing a surge in demand due to the rising prevalence of these diseases, coupled with advancements in radiopharmaceutical technology. Moreover, the growing awareness among healthcare professionals and patients about the benefits of nuclear medicine is fueling market expansion. In addition, the increasing investments in research and development activities to develop novel radiopharmaceuticals are expected to further boost market growth.
The Global Radiopharmaceuticals Market size is projected to reach 15,317.05 million by 2030, at a CAGR of 6.5% during the forecast period of 2023-2030.
To know more, visit https://www.databridgemarketresearch.com/es/reports/global-radiopharmaceuticals-market
Below are the Top Five Radiopharmaceuticals Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Cardinal Health
|
Cardinal Health is a key player in the global radiopharmaceuticals market, offering a wide range of products and services in the nuclear medicine field. The company is known for its innovative solutions and high-quality radiopharmaceuticals, which are used in diagnostic imaging and targeted therapy for various medical conditions. Cardinal Health's strong distribution network and strategic partnerships enable it to reach a broad customer base worldwide. With a focus on patient safety and quality assurance, Cardinal Health is committed to providing reliable and effective radiopharmaceutical products to healthcare providers, contributing to the advancement of nuclear medicine and the overall growth of the global radiopharmaceuticals market.
|
PET
|
North America, Middle East and Africa, Europe, Asia- Pacific
|
In October 2022, Cardinal Health was recognized by Forbes as one of America's Best Large Employers company 2022 through an independent survey taken by approximately 60,000 American employees working for U.S. companies. The company believes this will inspire them and will give motivation to their employees
|
|
2.
|
Advanced Accelerator Applications
|
Advanced Accelerator Applications (AAA) is a leading company in the global radiopharmaceuticals market, specializing in the development, production, and commercialization of molecular nuclear medicine (MNM) products. The company's innovative approach focuses on targeted radioligand therapies and diagnostic radiopharmaceuticals for precision oncology. AAA's flagship product, Lutathera, is a peptide receptor radionuclide therapy (PRRT) used for the treatment of neuroendocrine tumors (NETs). The company has a strong presence in Europe, North America, and other regions, with a commitment to advancing personalized medicine through its cutting-edge radiopharmaceutical products. AAA's dedication to research and development, along with its focus on collaboration and partnerships, positions it as a key player in driving innovation and growth in the global radiopharmaceuticals market.
|
|
North America, Europe
|
In December 2022, Novartis received the European Commission approval for Pluvicto as the first targeted radioligand therapy for treatment of prostate cancer. The company believes that this will help in advancing a broad portfolio of radioligand therapies to treat cancer
|
|
3.
|
Lantheus
|
Lantheus Holdings, Inc., is a leading company in the global radiopharmaceuticals market, specializing in the development, manufacturing, and commercialization of diagnostic imaging agents and products. The company's portfolio includes a variety of radiopharmaceuticals used in nuclear medicine imaging procedures, such as technetium-based imaging agents for cardiovascular, oncology, and other diagnostic applications. Lantheus is known for its commitment to innovation, quality, and patient safety, and its products are used by healthcare providers worldwide to diagnose and manage a range of medical conditions.
|
|
North America, Europe
|
In April 2023, Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer. The company stated that the radioligand therapy is quickly becoming another pillar of cancer treatment.
|
|
4.
|
Curium
|
Curium is a leading global supplier of diagnostic and therapeutic radiopharmaceuticals for the nuclear medicine industry. Curium offers a wide range of products including imaging agents, therapeutic radiopharmaceuticals, and generators used in molecular imaging and targeted radiation therapy. The company serves healthcare providers in over 60 countries and is known for its commitment to quality, safety, and innovation in nuclear medicine. Curium's comprehensive product portfolio and strong global presence make it a key player in the market.
|
|
North America, Europe, Asia- Pacific
|
In May 2021, Curium finalized its acquisition of IASON, an Austrian radiopharmaceuticals company, further enhancing its presence in Europe and bolstering its extensive range of life-saving diagnostic solutions. This acquisition marks Curium's second purchase of a positron-emission-tomography (PET) radiopharmaceutical business in the same year, following its earlier acquisition of M2i, a prominent Irish PET player. As part of the deal, certain non-core businesses, including a portfolio of real estate properties, were divested to a consortium of entrepreneurs.
|
|
5.
|
GE HealthCare
|
GE Healthcare, a subsidiary of General Electric Company, is a global leader in the healthcare industry, including the field of radiopharmaceuticals. The company offers a wide range of imaging agents and radiopharmaceuticals used in diagnostic imaging procedures, including positron emission tomography (PET) and single-photon emission computed tomography (SPECT). GE Healthcare's innovative products and technologies help healthcare providers worldwide to diagnose and treat various medical conditions, including cancer, cardiovascular diseases, and neurological disorders.
|
PET AND SPECT
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In April 2017, GE Healthcare signed agreement with HealthTrust to supply radiopharmaceuticals. The company believes that this agreement will help in expanding availability of products to a greater number of hospitals around the country to advance diagnostic capabilities
|
Conclusion
The global radiopharmaceutical market is experiencing significant growth, driven by increasing applications in diagnostic imaging and targeted therapy. Companies such as Cardinal Health, Advanced Accelerator Applications (AAA), GE Healthcare, Lantheus, and Curium are at the forefront of driving innovation and meeting the rising demand for radiopharmaceuticals worldwide. With the increasing adoption of nuclear medicine and the development of novel radiopharmaceuticals, the market is expected to continue its growth trajectory in the coming years. Companies that can effectively innovate, collaborate, and meet the evolving needs of healthcare providers and patients are likely to drive further advancements in the field and capitalize on the expanding market opportunities.
